Parkinson’s Disease Studies

If you think you may qualify for one of these studies, please contact CNI’s Research Department at 303-806-7423.

BCI: Development of a Brain Computer Interface Program for Research

Parkinson’s disease interferes with starting tasks, such as walking, as well as switching between tasks. Parkinson’s disease also interferes with switching from one thought to another. This “switching” brain function is located in the frontal lobe, a region of the brain directly connected to areas treated with Deep Brain Stimulation. We strive to understand brain functions involved in this mental flexibility to quickly switch from one task to another. Adults with and without movement disorders such as Parkinson’s disease and Essential Tremor are eligible to participate in this study. While wearing an EEG cap to record brain waves, participants will be asked to perform simple tasks that involve moving a part of the body, speaking, writing, and switching. Research sessions will last approximately 2 hours.

Enrollment is on hold – please check back at this site for updates
Principal Investigator: Adam Hebb, MD
Research Coordinator: Joshua Nedrud (303.812.6422)

ACTIVA PC+S: LFP Correlates of Movement Disorders

The goal of this research is to further understand the activity of neurons in areas of the brain that are affected by Parkinson’s disease.  New recording Deep Brain Stimulation (DBS) technology is able to sense patients’ brain signals and predict what they are planning to do next.

Subjects in this study will receive the Medtronic Activa® PC+S, a new investigational device that records brain waves as well as provides proven DBS therapy.  Brain signals of those subjects will be recorded while they perform simple tasks such as walking, moving their arms, and reciting words. Information gained in this study may advance an understanding of how these brain signals control behaviors to aid in developing the next generation of DBS systems that can dynamically adjust to a patient’s goals.

eligibility and information – Closed to enrollment
Principal Investigator: Adam Hebb, MD

Intrepid: Implantable Neurostimulator for the Treatment of Parkinson’s Disease

This study investigates the safety and effectiveness of a medical device called Vercise (recently FDA-approved), for the treatment of Parkinson’s disease (PD) in patients whose disease is not adequately controlled by medications.  The study will evaluate changes in patients’ quality of life, PD medications, and severity of dyskinesia (uncontrolled movements) as well as other PD symptoms.

eligibility and information – Closed to enrollment
Principal Investigator: Monique Giroux, MD


Colorado Neurological Insitute